



Session Title:

The Next Era of CAR-T Development: What we've learned so far and what's to come in designing safer trials

Speakers:

Tanmay Jain - Senior Director, Medidata Acorn AI

With six regulatory approvals already in the first half of 2022 and 500 ongoing trials, CAR-T development is entering a new phase in its maturity curve and the coming years will hopefully see hundreds of programs moving into pivotal trials. While CAR-T treatments have shown promise in treating severely-ill patients with indications ranging from hematology to malignancies to solid tumors; development of these therapies remains extremely challenging due to the frequency and severity of adverse events such as Cytokine Release Syndrome (CRS), Neurotoxicity and Cytopenia. 2021 saw dozens of trials were placed on clinical hold by regulators due to patient safety concerns. Even amongst approved treatments, the risk of these potentially life-threatening side effects hinder adoption by treating oncologists. Attend this session with Tanmay Jain, Senior Director of Medidata Acorn AI, to discuss some novel strategies that developers can adopt to overcome development challenges and how historical clinical trial data can be the key to developing safer treatments.